Problems › Corporate Strategy Consulting › Healthcare Providers
Most people who go looking for corporate strategy in healthcare providers have a panel or contract question, and the two have opposite answers. What makes this harder for healthcare providers is structural: downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it. Any credible answer therefore has to hold cost per episode and payer mix in the same view, which is exactly where most internal analysis stops because the two live in different systems.
Most people who go looking for corporate strategy in healthcare providers have a panel or contract question, and the two have opposite answers. What makes this harder for healthcare providers is structural: downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it. Any credible answer therefore has to hold cost per episode and payer mix in the same view, which is exactly where most internal analysis stops because the two live in different systems.
The distinction is not academic. Corporate strategy asks where to play: which value-based contracts and attributed lives to hold, what panels or facilities to buy or sell, how capital and risk move between units, and what the corporate centre does that justifies its cost. Business-unit strategy asks how to win: managing cost per episode inside a contract, shaping payer mix, growing or pruning panel size, and improving contribution per provider against a specific set of attributed lives. Both are legitimate; they use different evidence and produce different decisions.
The reason they get confused is that the symptom is often identical. Flat performance on value-based contracts looks the same whether the cause is one underperforming panel or a set of contracts whose attributed lives have no relationship to each other. The test is what happens when you disaggregate: if performance is uniform across panels, you have a cost-per-episode problem inside a single contract and the portfolio view will not find it. If the average is being made by one panel carrying two, you have a portfolio problem and no amount of episode-level analysis inside the weak panels will fix it.
The second thing corporate strategy is for, and the one most often skipped, is the parenting question — what the centre adds. A corporate centre earns its cost either by allocating risk across contracts better than the units would on their own, by supplying cost-per-episode data or payer-mix discipline the panels could not obtain alone, or by imposing contribution-per-provider targets the providers would not set themselves. If it does none of those, it is a tax on the panels, and the honest strategic answer may be to shrink it rather than to redirect it.
Corporate Strategy & Transformation (catalog id t5) runs the portfolio arithmetic — contribution per provider by panel, cost per episode against risk accepted, the overhead each contract actually carries — and produces the allocation view. Where the answer turns out to be a single-contract competitive question, it will say so and point at the narrower analysis rather than dressing a cost-per-episode problem in portfolio language.
These three together are the signature. One on its own usually points somewhere else.
✓ The group result on value-based contracts is flat and the panels inside it are not moving together
✓ Nobody can state what the corporate centre does that a panel could not manage on its own cost-per-episode data
✓ Risk under value-based contracts is allocated roughly in proportion to last year rather than to contribution per provider
The move that usually makes it worse. Running a portfolio review on a provider that is really one panel, which produces a recommendation to exit the contract that was about to become the answer.
It is for you if you run or finance a healthcare provider and the group result is flat and the units inside it are not moving together. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on a healthcare provider. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Competitive Positioning · sample company profile
The move. Sell coordinated care bundles directly to self-insured employers using existing clinic density and ASC capacity.
The leak it closes. Bypasses commercial payer take-rate (estimated 15–20% of premium) and prior-authorization friction, reducing denial leakage on these lives to near zero
The assumption it rests on. At least two of the five largest self-insured employers in the two metros will sign a 3-year direct contract within 18 months — the engine put the probability at 0.7.
| Investment required | $2M over 36 months ($800K Year 1, $700K Year 2, $500K Year 3) |
| Expected return | 6.0–9.0× on $2M investment |
| Revenue, year 1 | $0 incremental (pilot setup and first contract negotiations) |
| Revenue, year 2 | $4–6M incremental (2–3 employer contracts, 4,000–6,000 covered lives) |
| Revenue, year 3 | $12–18M incremental (5 employer contracts, 10,000–15,000 covered lives) |
| Exit criteria | Terminate pilot and redeploy 4 FTEs if fewer than 2 employer contracts signed by Month 18 OR if operating margin on employer channel falls below 6% for two consecutive quarters |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Corporate Strategy & Transformation, one of 29 engagements the platform runs. For healthcare providers it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.
Corporate strategy decides which businesses to be in and how capital moves between them. Business strategy decides how to win inside one of them. A single-market company has no corporate strategy question worth paying for — it has a competitive one. A group with three units and one balance sheet has both, and answering them in the wrong order is the common failure.
A portfolio review from a large firm is commonly £150k–£500k for eight to twelve weeks; boutiques and independents do narrower versions for £40k–£120k. The variance is driven almost entirely by how much primary data collection is in scope. If your own finance system can already produce contribution and capital by unit, most of that cost is buying analysis of numbers you already hold.
As a summary, yes; as a decision rule, no. Growth and share are two of the variables that matter and they are the easiest two to obtain, which is why the matrix persists. It becomes misleading when a unit with modest share is the one generating the cash that funds everything else, and the grid says to divest it. Use it to organise the conversation, then decide on return against capital consumed.
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית